Kanaph Therapeutics카나프테라퓨틱스

Kanaph Therapeutics is a loss-making early-stage drug developer whose shares have fallen sharply since its March 2026 listing.

The company develops cancer and eye-disease drugs using bispecific antibodies, antibody-drug conjugates and small molecules, and earns revenue mainly from technology transfer and joint development deals. For the trailing twelve months to H1 2026 it reported revenue of ₩5.56B, an operating loss of ₩4.27B and a net loss of ₩35.56B, with cash of ₩10.14B. The share price closed at ₩10,090 on 2026-10-23, with a market cap of about ₩134.2B.

What stands out

• Revenue of ₩5.56B against an operating loss of ₩4.27B gives an operating margin of -76.8%; the data does not explain why the net loss (₩35.56B) is much larger than the operating loss.
• Free cash flow was -₩7.24B on the trailing figures, and the data shows no borrowings, with liabilities at 4.4% of equity.
• The stock is down 15.8% over one month and 17.7% over three months, and sits far below its 52-week high of ₩70,000; a one-year return is not available because it listed in March 2026.
• Price-to-book is 2.9 and price-to-sales is 24.1; P/E and EV/EBITDA are not meaningful because earnings are negative. The company pays no dividend.
• Foreign ownership fell from 4.7% to 3.1% over 60 days, and foreign investors were net sellers over 20 days, while retail investors were net buyers. The company's recent headlines focus on pipeline data presented at the World ADC conference in October.

What to watch

• The data does not include a scheduled date for the next quarterly or half-year results, so the timing of the next financial update is unknown.
• Stock purchase option grants were announced on 2026-05-28 and 2026-10-22, which could mean future share dilution; the data does not give the size of the grants.
• The internal fair value model gives a base value of ₩2,108 per share, well below the recent price, but its bear case (₩2,371) is higher than its base and bull cases, so the model's reliability is unclear; the data does not say what drives the gap.